Suzetrigine prevents pain signals from reaching the brain and doesn't give an opioid-like high, making it non-addictive—but ...

Federal officials have approved new pain medication Journavx, designed to offer short-term pain relief without the addiction and overdose risks associated with opioids like Vicodin and OxyContin. The ...

A new class of non-opioid drugs treats pain by blocking signals before they reach the brain, reducing the risk of addiction.

One participant in the drug trial for Journavx said it eliminated her pain without making her feel loopy or nauseous, which ...

Suzetrigine, being sold as Journavx, is the first new pharmaceutical pain treatment approved by the FDA in 20 years ...

The U.S. Food and Drug Administration (FDA) has approved Journavx, a new pain reliever without the risks of addiction or ...

The medication offers relatively modest pain relief, underscoring the challenges of finding new ways to manage pain.

The drug, Journavx, from Vertex Pharmaceuticals, reduced pain after surgery in clinical trials. Experts hope it can lead to fewer opioid prescriptions.

The new non-opioid drug has been approved for the treatment of severe pain, such as that following surgery or an injury.

A study published in Pain Reports adds a new piece to the puzzle ... acting through its effect on 5HT2A [5-hydroxytryptamine (serotonin) 2A] receptors, may have a preferential effect on reducing ...